Back to Results

Anteris Technologies Global Inc (AVR)

Anteris Technologies Global Inc is a healthcare company listed on the NASDAQ under the ticker AVR. The company focuses on structural heart therapies and develops minimally invasive medical devices for the treatment of heart valve disease. Its product portfolio includes the DurAVR transcatheter heart valve system, designed for patients with severe aortic stenosis, as well as the ADAPT anti-calcification tissue platform, which is used to create durable bioscaffolds for surgical repair applications, including aortic valve replacement. Anteris also develops the ComASUR delivery system, a balloon-expandable platform with a reinforced steerable catheter intended to support controlled navigation through heart anatomy. The company is based in Toowong, Australia.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-AVR
$6.30
-22.8% Downside
Overvalued
$15.33
87.9% Upside
Bargain
Fair
0.0%
November 18, 2026
3.2x
354.7x
795.3 M
542 M
0.4%
67.7%
14.1
85.2%
Valuation • Fair Value

Anteris Technologies Global Inc (NASDAQ-AVR) Fair Value by Valuation Model

Review the available estimates for Anteris Technologies Global Inc (NASDAQ-AVR), including Comps Fair Value.

Primary Valuation Read

Fair Value

$6.30

Estimated downside of 22.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$6.30

Comparable-company valuation reference.

Analyst Price Target

$15.33

Analysts imply upside of 87.9%.

How to read these valuation models

Use the 4 available valuation references for Anteris Technologies Global Inc (NASDAQ-AVR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Anteris Technologies Global Inc (NASDAQ-AVR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

2.242 M

Current operating scale indicator.

Revenue Forecast

7.231 M

Forward revenue estimate.

EBITDA

-104.5 M

Current operating profitability reference.

EBITDA Forecast

-122.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Anteris Technologies Global Inc (NASDAQ-AVR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Anteris Technologies Global Inc (NASDAQ-AVR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.93

No elevated caution signal from this screen.

Altman Z-Score

14.1

Relatively strong balance-sheet zone.

FCF / Net Income

85.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Anteris Technologies Global Inc (NASDAQ-AVR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Anteris Technologies Global Inc (NASDAQ-AVR)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 18, 2026

Days to Earnings

61

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Anteris Technologies Global Inc (NASDAQ-AVR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Anteris Technologies Global Inc (NASDAQ-AVR) Stock Forecast & Technical Outlook

Review Anteris Technologies Global Inc (NASDAQ-AVR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Anteris Technologies Global Inc (NASDAQ-AVR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Anteris Technologies Global Inc (NASDAQ-AVR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Anteris Technologies Global Inc (NASDAQ-AVR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Anteris Technologies Global Inc (NASDAQ-AVR) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Anteris Technologies Global Inc (NASDAQ-AVR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Anteris Technologies Global Inc (NASDAQ-AVR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Anteris Technologies Global Inc (NASDAQ-AVR) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Anteris Technologies Global Inc (NASDAQ-AVR) Stock FAQ

Data-supported answers about Anteris Technologies Global Inc (NASDAQ-AVR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$6.30
Estimated downside 22.8%
Valuation Rating
Overvalued
Estimated downside of 22.8%
Analyst Target
$15.33
Implied upside 87.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Anteris Technologies Global Inc (NASDAQ-AVR) is $6.30. This implies an estimated downside of 22.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 22.8% versus the current market price.

The available analyst price target for Anteris Technologies Global Inc (NASDAQ-AVR) is $15.33. The analyst target implies estimated upside of 87.9%.

The current financial health read for Anteris Technologies Global Inc (NASDAQ-AVR) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Anteris Technologies Global Inc (NASDAQ-AVR) is November 18, 2026.

The latest available data indicates no current dividend yield for Anteris Technologies Global Inc (NASDAQ-AVR).

The current market capitalization listed for Anteris Technologies Global Inc is 795.3 M.

The current enterprise value listed for Anteris Technologies Global Inc is 542 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Anteris Technologies Global Inc is NASDAQ-AVR, and the stock is listed on NASDAQ.

Anteris Technologies Global Inc (NASDAQ-AVR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Anteris Technologies Global Inc is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Anteris Technologies Global Inc is 67.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 177.6 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 139 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 117.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 62.81 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 50.873 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.286 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 41.807 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 40.289 B
DXCM NASDAQ DexCom Inc Fair Value Fair Market Cap 33.717 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 32.188 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.559 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 28.967 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.25 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 19.991 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 18.189 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.123 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.51 B
BAX NYSE Baxter International Inc Fair Value Undervalued Market Cap 11.788 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.577 B